

INVITATION TO COMMENT ON A POSSIBLE ARTICLE 9 REQUEST

8 January 2016

This invitation to comment concerns the anticipated acquisition by McKesson Deutschland GmbH & Co KGaA (McKesson) of the united drug division and other associated businesses of UDG Healthcare plc (the Proposed Concentration) which we expect to be notified to the European Commission (EC) by mid-January 2016 by way of a Form CO.

Following completion of the Proposed Concentration, McKesson would acquire the share capital of certain companies (and, indirectly, the subsidiaries of such companies) within UDG Healthcare.

In particular, McKesson will acquire the sole control of the following businesses from UDG Healthcare which are active in the UK:

- The 'UD Wholesale Business' which offers distribution, wholesaling and related services in relation to pharmaceuticals and other products; and
- The 'MASTA Business', which offers wholesale supply of flu and travel vaccines, and also offers travel advice and vaccinations through its network of private health clinics

McKesson will also acquire from UDG Healthcare certain businesses active in the Republic of Ireland which are outside the scope of this invitation to comment.

The above merger meets the thresholds for review under Council Regulation 139/2004/EC (ECMR) and has therefore been notified to the EC. The Competition and Markets Authority (CMA) is considering whether the acquisition of the UK aspects of UDG Healthcare's businesses (i) qualifies for a request to be made under Article 9 of the ECMR to have the merger case referred to the United Kingdom authorities; and if so, (ii) whether it would be appropriate for the CMA to make a request under Article 9 of the ECMR for the case to be referred in whole or in part to the United Kingdom authorities.

If any such request were made by the UK and the EC decided to grant such a request, the CMA would examine the merger situation further with a view to deciding

whether or not the merger should be referred for an in-depth investigation under the provisions of the Enterprise Act 2002.

The CMA seeks views on: (i) the appropriateness of the merger being referred to the CMA for investigation; and (ii) whether the merger may be expected to result in a substantial lessening of competition within any market(s) in the UK. Given the short amount of time the CMA has to make any request to the EC, any representations should arrive by 15 January 2016.

Please send written representations about any implications the merger may have for competition in the UK to:

Jean-François Guillaudeau
Competition and Markets Authority
Victoria House
Southampton Row
London
WC1B 4AD

Jean-francois.guillaudeau@cma.gsi.gov.uk

8 January 2016